A systematic review and meta-analysis suggests that angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) may be associated with protective effects for patients with COVID-19. The analysis included 52 studies that evaluated clinical outcomes among 101 949 total patients, of whom 26.0% were receiving ACEIs or ARBs. When adjusted for covariates, significant reductions in the risk of death (adjusted odds ratio [aOR], 0.57) and severe adverse events (AEs, aOR, 0.68) were found. Unadjusted and adjusted analyses of a subgroup of patients with high blood pressure indicated decreases in the risk of death (unadjusted OR, 0.66; aOR, 0.51) and severe AEs (unadjusted OR, 0.70; aOR, 0.55). The findings are consistent with previous meta-analysis in patients with high blood pressure, extend to patients with multiple mixed comorbidities, and support the recommendations of medical societies to continue receiving ACEIs and ARBs for patients with COVID-19. Source: https://jamanetwork.com/
Two recent studies highlight the importance of physical activity volume and intensity in reducing cardiovascular…
A prospective UK cohort study found that both self-reported average or brisk walking pace and…
A U.S. randomized clinical trial found that 4:3 intermittent fasting (IMF) led to slightly greater…
A Danish nationwide cohort study provided real world evidence that both glucagon-like peptide 1 receptor…
A systematic review and meta-analysis of placebo-controlled randomized trials showed that there is moderate certainty…
A US cohort study indicated that statin use may reduce the risks of hepatocellular carcinoma…
This website uses cookies.